Junichi Shoda, Tetsuo Miura, Hirotoshi Utsunomiya, Koji Oda, Masahiro Yamamoto, Masahito Kano, Tadashi Ikegami, Naomi Tanaka, Hidetaka Akita, Kousei Ito, Hiroshi Suzuki, Yuichi Sugiyama – 5 January 2004 – Inchin‐ko‐to (ICKT), an herbal medicine, and its ingredients exert potent choleretic effects by a “bile acid‐independent” mechanism. The current study was designed to determine whether ICKT or its ingredients potentiate multidrug resistance‐associated protein 2 (Mrp2; Abcc2)‐mediated choleresis in vivo.

Dominique Roulot, Claude Degott, Olivier Chazouillères, Frédéric Oberti, Paul Calès, Nicolas Carbonell, Said Benferhat, Solange Bresson‐Hadni, Dominique Valla – 5 January 2004 – Unexplained liver test abnormalities are frequent in patients with Turner's syndrome. This cohort study was performed to clarify the histopathologic features, causes, and long‐term outcome of liver involvement in these patients. Thirty patients with persistently abnormal liver test results were followed‐up for 8.8 ± 5.2 years. Liver specimens were available in 27 patients.

Kittichai Promrat, Glen Lutchman, Gabriel I. Uwaifo, Renee J. Freedman, Alejandro Soza, Theo Heller, Edward Doo, Marc Ghany, Ahalya Premkumar, Yoon Park, T. Jake Liang, Jack A. Yanovski, David E. Kleiner, Jay H. Hoofnagle – 5 January 2004 – Nonalcoholic steatohepatitis (NASH) is a common chronic liver disease for which there is no known effective therapy. A proportion of patients with NASH progress to advanced fibrosis and cirrhosis. NASH is considered one of the clinical features of the metabolic syndrome in which insulin resistance plays a central role.

Harvey J. Alter – 5 January 2004

Andres T. Blei – 5 January 2004

Juliette Martin, Jean‐François Dufour – 5 January 2004 – Background & Aims: Cholestasis is one of the principal manifestations of liver disease and often results from disorders involving bile duct epithelia rather than hepatocytes. A range of disorders affects biliary epithelia, and no unifying pathophysiologic event in these cells has been identified as the cause of cholestasis.

Hiroyuki Katagiri, Yoshiya Ito, Ken‐ichiro Ishii, Izumi Hayashi, Makoto Suematsu, Shohei Yamashina, Takahiko Murata, Shuh Narumiya, Akira Kakita, Masataka Majima – 5 January 2004 – Although thromboxanes (TXs), whose synthesis is regulated by cyclooxygenase (COX), have been suggested to promote inflammation in the liver, little is known about the role of TXA2 in leukocyte endothelial interaction during endotoxemia.

M. Eugenia Guicciardi, Gregory J. Gores – 30 December 2003

Jacquelyn J. Maher – 30 December 2003

Jean‐Louis Payen, Jacques Izopet, Virginie Galindo‐Migeot, Valérie Lauwers‐Cances, Jean‐Pierre Zarski, Jean‐Marie Seigneurin, Elizabeth Dussaix, Jean‐Jacques Voigt, Janick Selves, Karl Barange, Jacqueline Puel, Jean‐Pierre Pascal, Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.vhc) – 30 December 2003 – We studied the efficacy of three interferon alfa‐2b (IFN‐α2b) regimens for the retreatment of patients with chronic hepatitis C (CHC) with prior complete response followed by relapse.